The Latest Breaking News from Eli Lilly

March S&P 500 E-Mini futures (ESH25) are up +0.05%, and March Nasdaq 100 E-Mini futures (NQH25) are down -0.08% this morning as investors awaited a new round of U.S. economic data, remarks from Federal Reserve officials, and an earnings report from “Magnificent Seven” member Amazon.

March S&P 500 E-Mini futures (ESH25) are up +0.20%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.10% this morning, suggesting Wall Street is set to extend yesterday’s gains, while investors awaited a new round of U.S. economic data, remarks from Federal Reserve officials, and an earnings report from…

This weight-loss underdog doubled in a single day last week and could deliver even bigger rewards.

Eli Lilly's two major GLP-1 drugs have dominated headlines, but a slate of new treatments in development—and some already available—suggest a bright future.

The drug is subsidised for treatment of type 2 diabetes but experts say it could help reduce other health problems associated with severe obesity

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

Novo Nordisk stock surged Friday after the obesity kingpin reported strong results for its next-generation weight-loss drug, amycretin.

GLP-1 drugs have been all the rage for weight loss, but GE Healthcare and Novo Nordisk are working on a non-invasive approach to controlling metabolic functions

The stock market rebounded to or above key levels on tame inflation data and strong bank earnings. Many stocks flashed buy signals.